Gene therapy: Is IL2RG oncogenic in T-cell development?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature

• Publication date

  2006-09-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature05218PMID 16988660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T-sing progenitors to commit.

  2006cited by this paper
• Gene therapy: Therapeutic gene causing lymphoma

  2006cited by this paper
• Gene therapy put on hold as third child develops cancer

  2005cited by this paper
• New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling

  2005cited by this paper
• A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

  2003cited by this paper
• Second Child in French Trial Is Found to Have Leukemia

  2003cited by this paper
• Blood.

  1989cited by this paper
• Book ReviewMajor Sex-Determining Genes

  1980cited by this paper

• IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p

  2024influential citation
• Advances in gene therapy for inborn errors of immunity

  2023cites this paper
• The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use

  2023cites this paper
• Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease

  2020cites this paper
• Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency

  2020cites this paper
• Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID

  2020cites this paper
• Hematopoiesis and Lymphocyte Development: An Introduction

  2019cites this paper
• Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives

  2019cites this paper
• Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic stem cell populations?

  2018cites this paper
• Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.

  2018cites this paper
• Introduction on Primary Immunodeficiency Diseases

  2017cites this paper
• Application to Gene Therapy and Vaccination

  2017cites this paper
• Targeting oncogenic receptor : From molecular physiology to currently the standard of target therapy

  2017cites this paper
• Gene Therapy for the Treatment of Primary Immune Deficiencies

  2016cites this paper
• Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms.

  2016cites this paper
• Downregulating oncogenic receptor: From bench to clinic

  2016cites this paper
• Lentiviral hematopoietic stem cell gene therapy in inherited immune and lysosomal enzyme deficiencies

  2016cites this paper
• RNA-Based Therapies for Bone Diseases

  2015cites this paper
• Gene Therapy for SCID

  2015cites this paper
• Safety of gene therapy: new insights to a puzzling case.

  2014cites this paper
• Biosafety considerations using gamma-retroviral vectors in gene therapy.

  2014cites this paper
• Lentiviral Hematopoietic Stem Cell Gene Therapy in Inherited Metabolic Disorders

  2014cites this paper
• gene therapy transcriptional activity of T cells from ADA-SCID patients treated with Integration of retroviral vectors induces minor changes in the

  2014cites this paper
• Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.

  2013cites this paper
• Development of Safer Gene Delivery Systems to Minimize the Risk of Insertional Mutagenesis-Related Malignancies: A Critical Issue for the Field of Gene Therapy

  2012cites this paper
• Induced pluripotent stem cells and severe combined immunodeficiency: merely disease modeling or potentially a novel cure?

  2012cites this paper
• An investigation into factors affecting ultrasound and microbubble mediated gene transfection

  2012cites this paper
• Engineering humanized mice for improved hematopoietic reconstitution

  2012cites this paper
• Engineering Humanized Mice for Improved Hematopoietic Reconstitution Running Title : Improving Humanized Mice

  2012cites this paper
• Retroviral Integrations in Gene Therapy Trials

  2012cites this paper
• Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man

  2011cites this paper
• Investigation of the effects of virus integration on host gene expression in mouse tumour samples

  2011cites this paper
• Insertional Mutagenesis in Hematopoietic Cells: Lessons Learned from Adverse Events in Clinical Gene Therapy Trials

  2011cites this paper
• Introduction to gene therapy: a clinical aftermath.

  2011cites this paper
• Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.

  2011cites this paper
• Retroviral Vectors in Gene Therapy: Mechanism of Integration, Successes in Gene Therapy Trials, Emerging Problems and Potential Solutions

  2011cites this paper
• Chapter 2 Introduction to Gene Therapy : A Clinical Aftermath

  2011cites this paper
• The genomic risk of somatic gene therapy.

  2010cites this paper
• Murine Leukemias with Retroviral Insertions at Lmo2 Are Predictive of the Leukemias Induced in SCID-X1 Patients Following Retroviral Gene Therapy

  2009cites this paper
• Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.

  2009cites this paper
• Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.

  2009cites this paper
• Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.

  2009cites this paper
• From stem cells to bone: phenotype acquisition, stabilization, and tissue engineering in animal models.

  2009cites this paper
• Genotoxic Potential of Lineage-specific Lentivirus Vectors Carrying the β-Globin Locus Control Region.

  2009cites this paper
• Improving safety of gene therapy.

  2008cites this paper
• Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors

  2008cites this paper
• Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?

  2008cites this paper
• Integration Site Selection by Retroviral Vectors: Molecular Mechanism and Clinical Consequences

  2008cites this paper
• Genotoxicity in gene therapy: an account of vector integration and designer nucleases.

  2008cites this paper
• Recent advances in gene therapy for severe congenital immunodeficiency diseases

  2008cites this paper
• Retrovirus-induced oncogenesis and safety of retroviral vectors.

  2008cites this paper
• Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16

  2008cites this paper
• Clinical application of lentiviral vectors - concepts and practice.

  2008cites this paper
• Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications.

  2008cites this paper
• Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

  2008cites this paper
• Dendrimers and the double helix--from DNA binding towards gene therapy.

  2008cites this paper
• Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy.

  2008cites this paper
• An Introduction to Primary Immunodeficiency Diseases

  2008cites this paper
• The development of HIV-1 derived gene transfer technology: optimisation of vector safety, processing and production.

  2008cites this paper
• New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.

  2007cites this paper
• Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy

  2007cites this paper
• Monoclonal T-cell receptors: new reagents for cancer therapy.

  2007cites this paper
• [Gene therapy of SCID-X1].

  2007cites this paper
• Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy.

  2007cites this paper
• T-cell receptor gene therapy for cancer: the progress to date and future objectives

  2007cites this paper
• Insertional mutagenesis in gene therapy and stem cell biology

  2007cites this paper
• Gentherapie der SCID-X1

  2007cites this paper
• Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.

  2007cites this paper
• Novel insights into the development of T-cell acute lymphoblastic leukemia

  2007cites this paper
• Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy

  2007cites this paper
• Retroviral Integration Site Analysis and the Fate of Transduced Clones in an MDR1 Gene Therapy Protocol Targeting Metastatic Breast Cancer

  2007cites this paper
• Gene therapy: Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply)

  2006cites this paper
• Gene therapy of inherited immunodeficiencies.

  2003cites this paper